

**Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-Like Peptide-1 Therapy), Mode of Purchase (Over the Counter Purchase, Online Purchase) - Global Forecast to 2030**

Market Report | 2025-02-10 | 286 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The pen needles market is projected to reach USD 3.08 Billion by 2030 from USD 1.81 Billion in 2024 at a CAGR of 9.2% during the forecast period. The elderly are susceptible, due to their age, to insulin resistance, a decrease in pancreatic function, and other comorbid conditions, including hypertension and obesity, which raise the risk of developing diabetes. As people age, the body becomes less responsive to insulin's role in regulating blood sugar, hence increasing the chances of developing Type 2 diabetes. In addition, the reduction in physical activity among older adults, coupled with lifestyle changes, contributes to rising trends of the condition. The increasing incidence rate of diabetes with age has simple direct implications concerning the increased desire for insulin administration devices, especially the pen needles. Insulin injections are an essential component of diabetes management among elderly patients, especially patients with Type 1 or advanced Type 2 diabetes. Ease of use, convenience, and reduced pain compared to traditional syringes make the pen needle particularly suitable for older adults. Other conditions most of the elderly suffer from include arthritis, which could primarily hinder them using syringes, hence developing the preference for insulin pens that use pen needles.

"The standard pen needles segment is accounted for the largest share of global pen needles market."

The market share of pen needles in the global market is dominated by the standard ones because of their wide compatibility with most of the pen injectors used for insulin administration and other injectable drugs. These needles are developed to be able to fit in a variety of insulin pens, making them available to patients across all demographics. Their simplicity and affordability make them popular, and their ease of use is something that is found in regions whose populations are rather cost-sensitive. Standard

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

pen needles are also apt for Type 1 and Type 2 diabetes patients. Other patients also require injectable medications for some other conditions; hence, standard pen needles find wide usage in all these conditions, making the patients and their healthcare providers retain them as a first choice for their use.

"Online purchase segment will grow at the highest CAGR during the forecast period of the global pen needles market."

The online purchase segment of the global pen needles market is expected to have the highest growth rate during the forecast period due to the benefits and convenience that e-commerce platforms have provided. For instance, the websites provide competitive prices and, sometimes, offer discounts, promotional offers, and bundle deals that can make the purchase of pen needles cheaper for customers. Apart from this, the appeal of online shopping is greater than traditional retail shops due to more ease in product comparison, reading customer reviews, and availability of a comprehensive range of products and sizes. The availability on online platforms also increases the accessibility for customers located at remote locations or those with some mobility issues since they can receive their pen needles at home. E-commerce adoption, with more convenience and cost-effectiveness, ensures that the segment of online purchases is going to grow strongly.

"North America to witness the substantial growth rate during the forecast period."

The pen needles market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries based on the region type. In 2024, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounts for the largest market share of the pen needles market in 2024. This is largely because of the health care systems that are advanced to facilitate better access to diabetes care. The U.S. and Canada have a well-developed medical infrastructure, making it easy for patients to reach pen needles for insulin delivery devices. Furthermore, with millions of people suffering from diabetes in these regions, there is high demand for effective, as well as user-friendly, delivery solutions. Pen needles are popular for their convenience, ease of use, and minimal discomfort. It is the preferred way to manage Type 1 and Type 2 diabetes. With extensive healthcare coverage, a high patient awareness level, and a large diabetic population, North America is the most significant market for pen needles.

A breakdown of the primary participants (supply-side) for the pen needles market referred to for this report is provided below:

-□By Company Type: Tier 1-22%, Tier 2-36%, and Tier 3-42%

-□By Designation: C-level-23%, Director Level-28%, and Others-49%

-□By Region: North America-38%, Europe-29%, Asia Pacific-23%, Latin America- 6%, and Middle East and Africa- 1% and GCC Countries- 3%

Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US).

Research Coverage:

The market study covers the pen needles market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by type, length, application, mode of purchase, setting and region. The study

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

#### Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

- Analysis of Market Dynamics: Drivers (rising incidence of chronic diseases, favorable reimbursements in certain countries, and decreasing prices of insulin formulations) restraints (rising pet care costs, poor reimbursement scenario in emerging countries, and needle anxiety) opportunities (growing preference for biosimilar drugs, emerging economies to offer high-growth potential, and rising healthcare expenditure on diabetes), and challenges (implementation of regulations for safety pen needles, reuse of pen needles, and misuse of injection pens)
- Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the pen needles market.
- Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, end-user, and region.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the pen needles market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the pen needles market like Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), B. Braun SE (Germany), and Terumo Corporation (Japan).

#### Table of Contents:

1	INTRODUCTION	24
1.1	STUDY OBJECTIVES	24
1.2	MARKET DEFINITION	24
1.2.1	INCLUSIONS & EXCLUSIONS	25
1.2.2	MARKET SEGMENTATION	26
1.2.3	YEARS CONSIDERED	27
1.2.4	CURRENCY CONSIDERED	27
1.3	LIMITATIONS	28
1.4	STAKEHOLDERS	28
1.5	SUMMARY OF CHANGES	28
2	RESEARCH METHODOLOGY	30
2.1	RESEARCH DATA	30
2.1.1	SECONDARY DATA	30
2.1.1.1	Key data from secondary sources	31
2.1.2	PRIMARY DATA	32
2.1.2.1	Key data from primary sources	33
2.1.2.2	Key industry insights	34
2.2	MARKET SIZE ESTIMATION	36
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	42
2.4	MARKET SHARE ANALYSIS	43
2.5	METHODOLOGY-RELATED LIMITATIONS	43
2.6	STUDY ASSUMPTIONS	43

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.7	RISK ASSESSMENT	44
3	EXECUTIVE SUMMARY	45
4	PREMIUM INSIGHTS	49
4.1	PEN NEEDLES MARKET OVERVIEW	49
4.2	ASIA PACIFIC: PEN NEEDLES MARKET, BY LENGTH AND COUNTRY (2024)	50
4.3	GEOGRAPHIC GROWTH OPPORTUNITIES	51
4.4	REGIONAL MIX	51
5	MARKET OVERVIEW	52
5.1	INTRODUCTION	52
5.2	MARKET DYNAMICS	52
5.2.1	DRIVERS	53
5.2.1.1	Rising incidence of chronic diseases	53
5.2.1.2	Favorable reimbursements in certain countries	54
5.2.1.3	Growing adoption of self-administration	54
5.2.1.4	Decreasing prices of insulin formulations	55
5.2.2	RESTRAINTS	56
5.2.2.1	Alternative methods of drug delivery	56
5.2.2.2	Poor reimbursement scenario in emerging markets	56
5.2.2.3	Needle anxiety	56
5.2.3	OPPORTUNITIES	57
5.2.3.1	Growing preference for biosimilar drugs	57
5.2.3.2	Emerging economies to offer high-growth potential	57
5.2.3.3	Rising healthcare expenditure on diabetes	57
5.2.3.4	Implementation of regulations for safety pen needles	58
5.2.4	CHALLENGES	58
5.2.4.1	Reuse of pen needles	58
5.2.4.2	Misuse of injection pens	59
5.3	INDUSTRY TRENDS	59
5.3.1	GROWING PREFERENCE FOR SAFETY-ENGINEERED PEN NEEDLES	59
5.3.2	RISING ADOPTION OF SHORTER AND ULTRA-THIN NEEDLES	60
5.4	REIMBURSEMENT SCENARIO	61
5.5	PRICING ANALYSIS	62
5.5.1	INDICATIVE SELLING PRICE OF PEN NEEDLES, BY KEY PLAYER, 2024	62
5.5.2	AVERAGE SELLING PRICE TREND OF STANDARD PEN NEEDLES, BY REGION, 2022-2024	64
5.6	VALUE CHAIN ANALYSIS	64
5.7	ECOSYSTEM ANALYSIS	65
5.8	PORTER'S FIVE FORCES ANALYSIS	67
5.8.1	INTENSITY OF COMPETITIVE RIVALRY	68
5.8.2	BARGAINING POWER OF SUPPLIERS	68
5.8.3	BARGAINING POWER OF BUYERS	69
5.8.4	THREAT OF SUBSTITUTES	69
5.8.5	THREAT OF NEW ENTRANTS	69
5.9	SUPPLY CHAIN ANALYSIS	70
5.10	REGULATORY ANALYSIS	71
5.10.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	72
5.10.2	REGULATORY FRAMEWORK	75

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

5.10.2.1	North America	75
5.10.2.1.1	US	75
5.10.2.1.2	Canada	75
5.10.2.2	Europe	77
5.10.2.3	Asia Pacific	77
5.10.2.3.1	Japan	77
5.10.2.3.2	China	78
5.10.2.3.3	India	79
5.11	TRADE ANALYSIS	80
5.11.1	TRADE ANALYSIS OF NEEDLES, CATHETERS, AND CANNULAE USED IN MEDICAL, SURGICAL, DENTAL, OR VETERINARY SCIENCES (HS CODE 901839)	80
5.11.2	EXPORT DATA (HS CODE 901839), 2019-2023	80
5.11.3	IMPORT DATA (HS CODE 901839), 2019-2023	81
5.12	PATENT ANALYSIS	81
5.12.1	PATENT PUBLICATION TRENDS FOR PEN NEEDLES	81
5.12.2	INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS	82
5.13	KEY STAKEHOLDERS & BUYING CRITERIA	85
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS	85
5.13.2	BUYING CRITERIA	86
5.14	CASE STUDY ANALYSIS	87
5.14.1	CASE STUDY 1: IMPACT OF CCG-WIDE INSULIN PEN NEEDLE	87
5.14.2	CASE STUDY 2: PEN NEEDLE DESIGN INFLUENCES EASE INSERTION, PAIN, AND SKIN TRAUMA IN SUBJECTS WITH TYPE 2 DIABETES	88
5.14.3	CASE STUDY 3: DROPSAFE SAFETY PEN NEEDLE HELPS TO PREVENT ACCIDENTAL NEEDLESTICKS AFTER INJECTIONS	89
5.15	TECHNOLOGY ANALYSIS	89
5.15.1	KEY TECHNOLOGIES	89
5.15.1.1	Fluid flow enhancement technology	89
5.15.1.2	Ultra-thin needle technology	90
5.15.2	COMPLEMENTARY TECHNOLOGIES	90
5.15.2.1	Microfabricated needles	90
5.15.2.2	AI in pen injectors	90
5.15.3	ADJACENT TECHNOLOGIES	91
5.15.3.1	Autoinjectors	91
5.16	KEY CONFERENCES & EVENTS, 2025-2026	92
5.17	ADJACENT MARKET ANALYSIS	93
5.17.1	AUTOINJECTORS MARKET	93
5.17.2	INSULIN DELIVERY DEVICES MARKET	95
5.17.3	INJECTION PENS MARKET	96
5.17.4	NEEDLES MARKET	97
5.18	IMPACT OF AI/GEN AI ON PEN NEEDLES MARKET	97
5.19	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS	98
5.20	UNMET NEEDS ANALYSIS	99
5.21	INVESTMENT & FUNDING SCENARIO	100
?		
6	PEN NEEDLES MARKET, BY TYPE	102
6.1	INTRODUCTION	103

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.2	STANDARD PEN NEEDLES	103
6.2.1	GREATER PREFERENCE AND AFFORDABILITY OF STANDARD PEN NEEDLES TO SUPPORT GROWTH	103
6.3	SAFETY PEN NEEDLES	106
6.3.1	GROWING CONCERNS OVER NEEDLESTICK INJURIES TO DRIVE ADOPTION OF SAFETY PEN NEEDLES	106
7	PEN NEEDLES MARKET, BY LENGTH	108
7.1	INTRODUCTION	109
7.2	8MM	110
7.2.1	WIDE ADOPTION IN NORTH AMERICA TO BOOST MARKET GROWTH	110
7.3	5MM	112
7.3.1	SHORTER LENGTH AND LOW PAIN TO FUEL UPTAKE	112
7.4	6MM	114
7.4.1	FAVORABLE REIMBURSEMENTS TO BOOST DEMAND	114
7.5	4MM	116
7.5.1	WIDE ADOPTION IN PEDIATRIC INSULIN DELIVERY TO DRIVE DEMAND	116
7.6	12MM	118
7.6.1	HIGH UTILIZATION OF SHORTER NEEDLES TO LIMIT ADOPTION	118
7.7	10MM	120
7.7.1	PAINFUL PROCEDURES TO RESTRAIN ADOPTION	120
8	PEN NEEDLES MARKET, BY APPLICATION	122
8.1	INTRODUCTION	123
8.2	INSULIN THERAPY	123
8.2.1	RIISING INCIDENCE OF DIABETES TO PROPEL MARKET	123
8.3	GLUCAGON-LIKE PEPTIDE-1 THERAPY	125
8.3.1	GROWING FOCUS OF PHARMA COMPANIES ON GLP-1 DRUG DEVELOPMENT TO DRIVE MARKET	125
8.4	GROWTH HORMONE THERAPY	126
8.4.1	AVAILABILITY OF LONG-ACTING TREATMENTS TO AFFECT DEMAND FOR NEEDLES	126
8.5	OSTEOPOROSIS	128
8.5.1	RIISING VITAMIN D DEFICIENCY CASES TO PROPEL MARKET	128
8.6	OTHER APPLICATIONS	129
9	PEN NEEDLES MARKET, BY MODE OF PURCHASE	131
9.1	INTRODUCTION	132
9.2	PRESCRIPTION-BASED PURCHASE	132
9.2.1	RETAIL PURCHASES TO SUPPORT MARKET GROWTH	132
9.3	OTC PURCHASES	133
9.3.1	DISCOUNTS OFFERED BY LOCAL PHARMACIES, SUPPLIERS, AND DISTRIBUTORS TO DRIVE MARKET	133
9.4	ONLINE PURCHASE	134
9.4.1	CONVENIENCE AND TIME-EFFICIENT BENEFITS TO PROPEL MARKET	134
9.5	OTHER MODES OF PURCHASE	135
10	PEN NEEDLES MARKET, BY CARE SETTING	138
10.1	INTRODUCTION	139
10.2	HOME CARE SETTINGS	139
10.2.1	GROWING PREFERENCE FOR SELF-ADMINISTRATION OF INSULIN TO PROPEL MARKET	139
10.3	HOSPITALS & CLINICS	140
10.3.1	INCREASING ADOPTION OF SAFETY PEN NEEDLES TO DRIVE MARKET	140
10.4	OTHER CARE SETTINGS	142
11	PEN NEEDLES MARKET, BY REGION	143

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

11.1	INTRODUCTION	144
11.2	NORTH AMERICA	144
11.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	144
11.2.2	US	148
11.2.2.1	Increasing burden of diabetes to contribute to growth	148
11.2.3	CANADA	151
11.2.3.1	Growing initiatives for diabetic coverage to drive market	151
11.3	EUROPE	154
11.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	154
11.3.2	GERMANY	157
11.3.2.1	Advanced healthcare system to intensify growth	157
11.3.3	UK	160
11.3.3.1	High incidence of cardiovascular disease to favor growth	160
11.3.4	FRANCE	163
11.3.4.1	Growing delivery of insulin devices to propel market	163
11.3.5	ITALY	166
11.3.5.1	Low product pricing to support growth	166
11.3.6	SPAIN	168
11.3.6.1	Supportive regulations mandating the use of safety pen needles to propel market	168
11.3.7	REST OF EUROPE	171
11.4	ASIA PACIFIC	173
11.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	173
11.4.2	JAPAN	178
11.4.2.1	Growing inclination toward public health insurance to boost market	178
?		
11.4.3	CHINA	180
11.4.3.1	Rising focus on modernizing healthcare to expedite growth	180
11.4.4	AUSTRALIA & NEW ZEALAND	183
11.4.4.1	Increasing rate of chronic diseases to amplify growth	183
11.4.5	INDIA	185
11.4.5.1	Growing per capita income to fuel market	185
11.4.6	SOUTH KOREA	187
11.4.6.1	Increasing geriatric population to facilitate growth	187
11.4.7	SOUTHEAST ASIA	190
11.4.7.1	Booming medical tourism industry to drive market	190
11.4.8	REST OF ASIA PACIFIC	193
11.5	LATIN AMERICA	195
11.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	195
11.5.2	BRAZIL	197
11.5.2.1	Growing incidence of non-communicable diseases to drive market	197
11.5.3	MEXICO	200
11.5.3.1	Universal health coverage to stimulate growth	200
11.5.4	ARGENTINA	202
11.5.4.1	Increasing obesity rates to bolster growth	202
11.5.5	REST OF LATIN AMERICA	205
11.6	MIDDLE EAST & AFRICA	207
11.6.1	INCREASING PREVALENCE OF CHRONIC DISEASES TO AUGMENT GROWTH	207

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

11.6.2	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	207
11.7	GCC COUNTRIES	209
11.7.1	HIGHER DISPOSABLE INCOME TO ENCOURAGE GROWTH	209
11.7.2	MACROECONOMIC OUTLOOK FOR GCC COUNTRIES	210
12	COMPETITIVE LANDSCAPE	213
12.1	INTRODUCTION	213
12.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	213
12.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PEN NEEDLES MARKET	214
12.3	REVENUE ANALYSIS, 2019-2023	215
12.4	MARKET SHARE ANALYSIS, 2023	215
12.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	217
12.5.1	STARS	217
12.5.2	EMERGING LEADERS	217
12.5.3	PERVASIVE PLAYERS	217
12.5.4	PARTICIPANTS	218
12.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	219
12.5.5.1	Company footprint	219
12.5.5.2	Region footprint	220
12.5.5.3	Type footprint	221
12.5.5.4	Length footprint	222
12.5.5.5	Application footprint	223
12.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	224
12.6.1	PROGRESSIVE COMPANIES	224
12.6.2	RESPONSIVE COMPANIES	224
12.6.3	DYNAMIC COMPANIES	224
12.6.4	STARTING BLOCKS	224
12.6.5	COMPETITIVE BENCHMARKING	226
12.6.5.1	Detailed list of key startups/SMEs	226
12.6.5.2	Competitive benchmarking of key startups/SMEs	227
12.7	COMPANY VALUATION & FINANCIAL METRICS	227
12.8	COMPETITIVE SCENARIO	229
12.8.1	PRODUCT LAUNCHES & APPROVALS	229
12.8.2	DEALS	229
12.8.3	EXPANSIONS	230
12.9	BRAND/PRODUCT COMPARISON	231
12.10	R&D EXPENDITURE OF KEY PLAYERS	232
13	COMPANY PROFILES	233
13.1	KEY PLAYERS	233
13.1.1	EMBECTA CORP.	233
13.1.1.1	Business overview	233
13.1.1.2	Products offered	234
13.1.1.3	Recent developments	235
13.1.1.3.1	Deals	235
13.1.1.3.2	Expansions	235
13.1.1.3.3	Other developments	236
13.1.1.4	MnM view	236
13.1.1.4.1	Right to win	236

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 13.1.1.4.2 Strategic choices 236
- 13.1.1.4.3 Weaknesses & competitive threats 236
- 13.1.2 NOVO NORDISK A/S 237
- 13.1.2.1 Business overview 237
- 13.1.2.2 Products offered 238
- 13.1.2.3 Recent developments 239
- 13.1.2.3.1 Expansions 239
- 13.1.2.4 MnM view 239
- 13.1.2.4.1 Right to win 239
- 13.1.2.4.2 Strategic choices 239
- 13.1.2.4.3 Weaknesses & competitive threats 239
- ?
- 13.1.3 B. BRAUN SE 240
- 13.1.3.1 Business overview 240
- 13.1.3.2 Products offered 241
- 13.1.3.3 MnM view 242
- 13.1.3.3.1 Right to win 242
- 13.1.3.3.2 Strategic choices 242
- 13.1.3.3.3 Weaknesses & competitive threats 242
- 13.1.4 YPSOMED 243
- 13.1.4.1 Business overview 243
- 13.1.4.2 Products offered 245
- 13.1.4.3 Recent developments 245
- 13.1.4.3.1 Deals 245
- 13.1.4.4 MnM view 246
- 13.1.4.4.1 Right to win 246
- 13.1.4.4.2 Strategic choices 246
- 13.1.4.4.3 Weaknesses & competitive threats 246
- 13.1.5 TERUMO CORPORATION 247
- 13.1.5.1 Business overview 247
- 13.1.5.2 Products offered 248
- 13.1.5.3 MnM view 249
- 13.1.5.3.1 Right to win 249
- 13.1.5.3.2 Strategic choices 249
- 13.1.5.3.3 Weaknesses & competitive threats 249
- 13.1.6 NIPRO 250
- 13.1.6.1 Business overview 250
- 13.1.6.2 Products offered 251
- 13.1.6.3 Recent developments 252
- 13.1.6.3.1 Expansions 252
- 13.1.7 OWEN MUMFORD 254
- 13.1.7.1 Business overview 254
- 13.1.7.2 Products offered 254
- 13.1.7.3 Recent developments 255
- 13.1.7.3.1 Deals 255
- 13.1.8 ARKRAY, INC. 256
- 13.1.8.1 Business overview 256

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.8.2	Products offered	256
13.1.8.3	Recent developments	257
13.1.8.3.1	Expansions	257
13.1.9	ULTIMED, INC.	258
13.1.9.1	Business overview	258
13.1.9.2	Products offered	258
13.1.9.3	Recent developments	259
13.1.9.3.1	Product launches	259
13.1.10	HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.	260
13.1.10.1	Business overview	260
13.1.10.2	Products offered	260
13.1.11	MONTMED	261
13.1.11.1	Business overview	261
13.1.11.2	Products offered	261
13.1.11.3	Recent developments	261
13.1.11.3.1	Product approvals	261
13.1.11.3.2	Deals	262
13.1.12	HTL-STREFA	263
13.1.12.1	Business overview	263
13.1.12.2	Products offered	263
13.1.13	ALLISON MEDICAL, INC.	265
13.1.13.1	Business overview	265
13.1.13.2	Products offered	265
13.1.14	GLUCORX LIMITED	266
13.1.14.1	Business overview	266
13.1.14.2	Products offered	266
13.1.15	BERPU MEDICAL TECHNOLOGY CO., LTD.	267
13.1.15.1	Business overview	267
13.1.15.2	Products offered	267
13.2	OTHER PLAYERS	268
13.2.1	VAN HEEK MEDICAL	268
13.2.2	SIMPLE DIAGNOSTICS	269
13.2.3	IYON HEALTH MEDICAL	270
13.2.4	LINKS MEDICAL PRODUCTS INC.	271
13.2.5	MHC MEDICAL PRODUCTS, LLC	271
13.2.6	ADVACARE PHARMA	272
13.2.7	ARTSANA S.P.A.	273
13.2.8	PROMISEMED MEDICAL DEVICES, INC.	274
13.2.9	TRIVIDIA HEALTH, INC.	275
13.2.10	VOGT MEDICAL VERTRIEB GMBH	276
14	APPENDIX	277
14.1	DISCUSSION GUIDE	277
14.2	KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	282
14.3	CUSTOMIZATION OPTIONS	284
14.4	RELATED REPORTS	284
14.5	AUTHOR DETAILS	285

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-Like Peptide-1 Therapy), Mode of Purchase (Over the Counter Purchase, Online Purchase) - Global Forecast to 2030**

Market Report | 2025-02-10 | 286 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

Signature